By Dominic ChoppingGermany's Merck KGaA expects to gradually return to organic growth this year after reporting a slump in earnings during 2023, which it called a "transitional" year. Analysts expected 2023 pre-items Ebitda at EUR5.86 billion on net sales of EUR20.97 billion, according to consensus estimates provided by the company. Merck said the 2023 sales and earnings performance of the life science business sector was hurt by sharply lower Covid-19-related sales while the process solutions business slowed due to inventory destocking. The company expects slight to moderate organic sales and pre-items Ebitda growth in 2024. Write to Dominic Chopping at dominic.chopping@wsj.com(END) Dow Jones NewswiresMarch 07, 2024 01:45 ET (06:45 GMT)Copyright (c) 2024 Dow Jones & Company, Inc.

Source: Wall Street Journal March 07, 2024 08:42 UTC